Theralase Advances Research On Laser-Activated Photodynamic Compounds For Cancer Treatment
Laser-Activated Photodynamic Compounds For Cancer Treatment
Theralase Technologies, University Health Network, Ontario Centres of Excellence's Centre of Excellence for Photonics will expand their joint research and development of photodynamic compounds, which are activated by its TLC-3000 PDC super-pulsed biofeedback laser technology.
Roger White, President and CEO of Theralase Technologies Inc. stated that, "This is a significant milestone for the Company, which further expands research and development of the combined photodynamic compounds and laser technology for the selective destruction of cancers, bacterium, viruses and fat cells. The clinical applications of this technology, if proven successful, could have a significant impact on one of the more devastating diseases of our time."
Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology used in a wide range of bio-stimulation and bio-destruction clinical applications.
The Theralase technology platform targets several diverse healthcare sectors -- firstly, for non-invasive pain management and clinical therapy, in hundreds of neural muscular skeletal conditions, including arthritis -- secondly, to bio-stimulate and accelerate wound care and healing, including; bone fracture regeneration and osteoarthritic conditions -- and thirdly, combining photodynamic compounds with super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacterium, viruses and fat cells.